ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:
  • Octocog alfa (Advate) 250 IU, 500 IU, 1000 IU and 1500 IU powder and solvent for solution for injection
  • Rurioctocog alfa pegol (Adynovate) 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection
  • Nonacog alfa (BeneFIX) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection.

Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.

The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.


Recombinant blood products for prophylaxis and management of haemophilia A and B (19 December 2022)